Morepen Labs Secures ₹825 Crore Global CDMO Deal, Expands Manufacturing
Morepen Laboratories secured a multi-year CDMO mandate worth ₹825 crore from a global pharma major. Supplies are expected to start within 4-5 months, with execution through Q1 of the next financial year. This marks a significant expansion into the high-growth CDMO segment.
A ₹825 crore deal is a material development for Morepen Laboratories, representing a significant expansion into the CDMO segment and a major mandate in its history, likely impacting future revenue and market position.
The announcement details a significant new global deal, indicating business expansion and revenue growth, which is positive for the company.
Morepen Laboratories Limited has announced a significant multi-year Contract Development and Manufacturing Organization (CDMO) mandate valued at approximately ₹825 crore (USD 91 million) from a leading global pharma major.
Supplies under this new mandate are expected to commence within the next 4-5 months, with execution scheduled through the first quarter of the upcoming financial year. This engagement is considered one of the most substantial single CDMO mandates in the company's history, enabling it to scale its global manufacturing footprint.
The company's CDMO platform leverages over four decades of API manufacturing expertise and regulatory credibility, supporting collaborations with global pharmaceutical innovators through structured, multi-year supply programs. The mandate highlights Morepen's growing capabilities in regulated markets, supported by internationally accredited facilities, including USFDA, WHO-GMP, and EU approvals. Morepen is enhancing its capacity and technology investments to align with its expanding CDMO opportunity pipeline.
Mr. Sushil Suri, Chairman & Managing Director, stated that this mandate is an important milestone, reflecting customer confidence in Morepen's quality systems, regulatory track record, and execution capabilities. He views CDMO as a natural extension of the company's API strengths, creating additional avenues for scale, stability, and long-term value creation.
Mr. Kushal Suri, President – International Growth (API), added that the customer's confidence validates Morepen's credibility and its ability to qualify, execute, and deliver under regulated market expectations. Global pharmaceutical companies are increasingly consolidating supplier networks, favoring compliant, scalable, and reliable manufacturing platforms, a trend Morepen is well-positioned to capitalize on.
What to do with a filing like this
Morepen Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under new orders. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Morepen Laboratories Limited. Read the original for the full detail.